ClinicalTrials.gg
TerminatedNCT01011283Updated Oct 29, 2014Results posted

To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.

A Phase 4 interventional study of decitabine and azacitidine in Myelodysplastic Syndromes, sponsored by Eisai Inc.. Terminated at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-29.

Sponsored by Eisai Inc. · Phase 4, Interventional, and Treatment

Why this study was terminated
The study was stopped due to insufficient enrollment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies testing decitabine in Myelodysplastic Syndromes — 9 open to participants now, 16 under way, 1 of them phase 3. Decitabine · Myelodysplastic Syndromes.

Enrollment
46th of 74
26 · median 43
Started
2009
with 6 others
Phase 4
3 of 75
none open now
Registered
29th of 75
by date
Lead sponsor
7 of 75
Eisai Inc.

Among the 75 studies testing decitabine in Myelodysplastic Syndromes, this one is the 46th largest by enrollment of the 74 interventional ones that give a count, is one of 7 that started in 2009, is one of 3 in phase 4, and was the 29th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

9 of the 75 studies testing decitabine in Myelodysplastic Syndromes are open now, in 3 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About decitabine

Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies testing decitabine in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

The purpose of this study is to compare the response of patients with Intermediate or High Risk myelodysplastic syndromes (MDS) following treatment with decitabine or azacitidine.

03

Conditions studied

  • Myelodysplastic Syndromes

Keywords

  • MDS
  • Myelodysplastic Syndromes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects who meet all of the following criteria may be included in the study:

  1. Must have a diagnosis of primary myelodysplastic syndromes (MDS) of Intermediate-1 transfusion dependent, Intermediate-2, or High-risk [defined by International Prognostic Scoring System (IPSS) score of ≥0.5] and recognized French-American-British (FAB) classifications
  2. Male or female, 18 years of age or older with signed
  3. Adequate renal function
  4. Demonstrated normal liver function
  5. Female subjects of childbearing age must have negative pregnancy test within 1 week of study entry and agree to use adequate for the duration of the trial and for a minimum of six months after last dose of decitabine or azacitidine received.
  6. Male subjects must agree to use adequate contraception for the duration of the trial and for a minimum of six months after last dose of decitabine or azacitidine received.

Exclusion criteria

Exclusion Criteria

Subjects who meet any of the following criteria will be excluded from participation in the study:

  1. Current use of radiotherapy for extramedullary disease for 2 weeks prior to entering study (permitted if > 2 weeks from study entry and if recovered from toxic effects of therapy)
  2. Systemic fungal, bacterial, or viral infection which is not controlled (i.e., ongoing signs or symptoms of infection and without improvement despite appropriate treatment)
  3. Pregnancy or current lactation
  4. Significant concurrent disease, illness, or psychiatric disorder
  5. Treatment with an agent 30 days prior to the first dose of decitabine or azacitidine
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Active comparator
    1

    Drug: decitabine

  • Active comparator
    2

    Drug: azacitidine

Interventions

  • decitabine 20 mg/m\^2 /day intravenous (IV) infusion for 5 days every 28 days

    Also known as: Dacogen (decitabine)

  • azacitidine 75 mg/m\^2 /day subcutaneous (SC) injection for 7 days every 28 days

    Also known as: Vidaza (azacitidine)

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR), Defined as Proportion of Patients Having Complete Response (CR) and Marrow Complete Response (mCR) After Completion of 3 Cycles of Study Drug.

    Based on Modified International Working Group Response Criteria for Altering Natural History of Myelodysplastic Syndromes. Complete Response: Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines. Persistent dysplasia will be noted. Peripheral blood Hgb ≥ 11 g/dL; Platelets ≥ 100 X 10\^9/L; Neutrophils ≥ 1.0 X 10\^9/Lb; Blasts 0%. Marrow Complete Response: Bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment. Peripheral blood: if hematological improvement responses, they will be noted in addition to marrow CR.

    Time frame: 13 Weeks

Secondary outcomes

  1. Overall Response Rate (ORR), Defined as Proportion of Patients Having Complete Response (CR) and Marrow Complete Response (mCR) After Completion of 6 Cycles of Study Drug.

    Based on Modified International Working Group Response Criteria for Altering Natural History of Myelodysplastic Syndromes. Complete Response: Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines. Persistent dysplasia will be noted. Peripheral blood Hgb ≥ 11 g/dL; Platelets ≥ 100 X 10\^9/L; Neutrophils ≥ 1.0 X 10\^9/Lb; Blasts 0%. Marrow Complete Response: Bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment. Peripheral blood: if hematological improvement responses, they will be noted in addition to marrow CR.

    Time frame: 36 Weeks

07

Results

Posted Sep 18, 2013

Participant flow

This study was recruited at 20 centers in U.S. during the period of Feb 2010 to Jan 2011.

Participant flow — Overall Study
MilestoneDecitabine 20 mg/m^2Azacitidine 75 mg/m^2
Started1313
Completed22
Not completed1111
Withdrew: Adverse event42
Withdrew: Progressive disease02
Withdrew: Terminated by sponsor55
Withdrew: Other22

Outcome measures

PrimaryOverall Response Rate (ORR), Defined as Proportion of Patients Having Complete Response (CR) and Marrow Complete Response (mCR) After Completion of 3 Cycles of Study Drug.

Based on Modified International Working Group Response Criteria for Altering Natural History of Myelodysplastic Syndromes. Complete Response: Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines. Persistent dysplasia will be noted. Peripheral blood Hgb ≥ 11 g/dL; Platelets ≥ 100 X 10\^9/L; Neutrophils ≥ 1.0 X 10\^9/Lb; Blasts 0%. Marrow Complete Response: Bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment. Peripheral blood: if hematological improvement responses, they will be noted in addition to marrow CR.

Time frame:
13 Weeks
Reported as:
Number · Percentage of Participants
Overall Response Rate (ORR), Defined as Proportion of Patients Having Complete Response (CR) and Marrow Complete Response (mCR) After Completion of 3 Cycles of Study Drug.
Percentage of ParticipantsDecitabine 20 mg/m^2Azacitidine 75 mg/m^2
Overall Response Rate00
Complete Response00
Marrow Complete Response00
Partial Response00
Stable Disease45.525.0
SecondaryOverall Response Rate (ORR), Defined as Proportion of Patients Having Complete Response (CR) and Marrow Complete Response (mCR) After Completion of 6 Cycles of Study Drug.

Based on Modified International Working Group Response Criteria for Altering Natural History of Myelodysplastic Syndromes. Complete Response: Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines. Persistent dysplasia will be noted. Peripheral blood Hgb ≥ 11 g/dL; Platelets ≥ 100 X 10\^9/L; Neutrophils ≥ 1.0 X 10\^9/Lb; Blasts 0%. Marrow Complete Response: Bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment. Peripheral blood: if hematological improvement responses, they will be noted in addition to marrow CR.

Time frame:
36 Weeks
Reported as:
Number · Percentage of Participants
Overall Response Rate (ORR), Defined as Proportion of Patients Having Complete Response (CR) and Marrow Complete Response (mCR) After Completion of 6 Cycles of Study Drug.
Percentage of ParticipantsDecitabine 20 mg/m^2Azacitidine 75 mg/m^2
Overall Response Rate9.18.3
Complete Response9.18.3
Marrow Complete Response00
Partial Response9.10
Stable Disease36.416.7

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Decitabine 20 mg/m^2—7/13 (53.8%)13/13 (100%)
Azacitidine 75 mg/m^2—7/13 (53.8%)13/13 (100%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventDecitabine 20 mg/m^2Azacitidine 75 mg/m^2
PancytopeniaBlood and lymphatic system disorders3/131/13
Febrile neutropeniaBlood and lymphatic system disorders2/132/13
ThrombocytopeniaCardiac disorders2/130/13
PneumoniaInfections and infestations2/130/13
AnemiaBlood and lymphatic system disorders1/131/13
AspergillosisInfections and infestations1/130/13
Neutropenia sepsisInfections and infestations0/131/13
DiverticulitisInfections and infestations0/131/13
SepsisInfections and infestations1/130/13
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/130/13
Most frequent other events
Showing 10 of 114
Most frequent other events
EventDecitabine 20 mg/m^2Azacitidine 75 mg/m^2
NauseaGastrointestinal disorders1/139/13
VomitingGastrointestinal disorders0/138/13
AnemiaBlood and lymphatic system disorders7/135/13
FatigueGeneral disorders5/137/13
NeutropeniaBlood and lymphatic system disorders6/136/13
ThrombocytopeniaBlood and lymphatic system disorders6/135/13
DiarrheaGastrointestinal disorders4/135/13
LeukopeniaBlood and lymphatic system disorders4/133/13
Injection site erythemaGeneral disorders0/134/13
Injection site reactionGeneral disorders0/134/13

Baseline characteristics

Age, Continuous
Age, Continuous(years)Decitabine 20 mg/m^2Azacitidine 75 mg/m^2Total
Mean73.8 ± 11.6070.8 ± 9.1372.3 ± 10.35
Sex: Female, Male
Sex: Female, Male(Participants)Decitabine 20 mg/m^2Azacitidine 75 mg/m^2Total
Female235
Male111021
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Decitabine 20 mg/m^2Azacitidine 75 mg/m^2Total
Hispanic or Latino022
Not Hispanic or Latino131124
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Decitabine 20 mg/m^2Azacitidine 75 mg/m^2Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White131225
More than one race000
Unknown or Not Reported000
08

Study locations

19 sites
  • Birmingham Hematology and Oncology Associates
    Birmingham, Alabama 35205, United States
  • Stanford University Cancer Center
    Stanford, California 94305, United States
  • Stockton Hematology Oncology
    Stockton, California 95204, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33619, United States
  • Pasco Pinellas Cancer Center
    New Port Richey, Florida 34652, United States
  • Gulf Coast Oncology
    St. Petersburg, Florida 33705, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Siouxland Haeatology - Oncology Associates
    Sioux City, Iowa 51101, United States
  • Center for Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • Sletten Cancer Institute
    Great Falls, Montana 59405, United States
  • Cornell Medical Center
    New York, New York 10021, United States
  • Carolinas Medical Center NorthEast NorthEast Oncology Associates
    Concord, North Carolina 28025, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Oncology and Hematology Care
    Cincinnati, Ohio 45242, United States
  • University of Pittsburgh School of Medicine
    Pittsburgh, Pennsylvania 15232, United States
  • Charleston Hematology Oncology Associates
    Charleston, South Carolina 29403, United States
  • Sarah Cannon Cancer Center
    Nashville, Tennessee 37203, United States
  • Utah Cancer Specialists
    Salt Lake City, Utah 84106, United States
  • Gunderson Clinic Ltd.
    La Crosse, Wisconsin 54601, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009 and a primary completion of Jan 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2009
First posted
Nov 11, 2009
Start
Nov 2009
Primary completionActual
Jan 2011
Results first posted
Sep 18, 2013
Last update
Oct 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01011283
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Nov 11, 2009
Start date
Nov 2009
Primary completion
Jan 2011
Results posted
Sep 18, 2013
Last update
Oct 29, 2014

Study contacts

Karen Stein
study director · Eisai Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Decitabine · Azacitidine

Start the discussion